Clinical Trial

A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)

Study acronym: IVOLGA
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II single-arm open-label study to investigate the efficacy and safety of volrustomig in women with FIGO 2018 stage IIIA to IVA cervical cancer who have not progressed following platinum-based concurrent chemoradiation therapy (CCRT).
Protocol Amendment History 1 change
notable Enrollment increased: 30 -> 37 participants 2026-05-20
Trial Details
NCT Number NCT06943833
Lead Sponsor AstraZeneca
Conditions Locally Advanced Cervical Cancer
Enrollment 37 participants
Start Date 2025-03-31
Primary Completion 2028-03-13 (estimated)
Study Completion 2029-03-13 (estimated)
Updated on ClinicalTrials.gov 2026-05-19